The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Official Title: My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Study ID: NCT02091141
Brief Summary: This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
Mayo Clinic Arizona, Phoenix, Arizona, United States
Highlands Oncology Group, Springdale, Arkansas, United States
Science 37, Inc, Culver City, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Moores UCSD Cancer Center; Dept Clinical Trials Office, La Jolla, California, United States
Eisenhower Medical Center, Rancho Mirage, California, United States
Stanford Comprehensive Cancer Center, Stanford, California, United States
Kaiser Permanente - Vallejo, Vallejo, California, United States
University of Colorado, Aurora, Colorado, United States
SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
Mayo Clinic, Jacksonville, Florida, United States
Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch, Orlando, Florida, United States
Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States
Florida Cancer Specialists, Research Department, West Palm Beach, Florida, United States
University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States
Northeast Georgia Medical Center; Oncology Research Dept-5C, Gainesville, Georgia, United States
Southeastern Regional Medical Center, Inc., Newnan, Georgia, United States
Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst, Chicago, Illinois, United States
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
Midwestern Regional Med Center, Zion, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Mayo Foundation, Rochester, Minnesota, United States
Research Medical Center - Antibiotic Research Associates, Inc., Kansas City, Missouri, United States
Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment, Albuquerque, New Mexico, United States
University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment, Albuquerque, New Mexico, United States
University of New Mexico, Albuquerque, New Mexico, United States
San Juan Oncology Associates, Farmington, New Mexico, United States
Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States
Weill Cornell Univ Medical Ctr; Breast Cancer Center, New York, New York, United States
Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Univ No Carolina School of Med; Physicians Office Bldg, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
Wake Forest Univ Health Svcs; Internal Medicine, Winston-Salem, North Carolina, United States
Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States
Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
University Hospitals of Cleveland, Cleveland, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Providence Portland Medical Center, Portland, Oregon, United States
Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Eastern Regional Medical Ctr, Philadelphia, Pennsylvania, United States
UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Abington Mem Hosp-Abington; Rose. Can Ctr,Gyn Onc Ins, Willow Grove, Pennsylvania, United States
Sanford Cancer Cnt Onco Clinic, Sioux Falls, South Dakota, United States
SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
West Clinic, Germantown, Tennessee, United States
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Clinic, Nashville, Tennessee, United States
The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States
MD Anderson, Houston, Texas, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Northwest Medical Specialties, Tacoma, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR